Pomegranate juice: a small blood pressure effect in a sugary glass

The best supported effect of pomegranate juice is on blood pressure, and it is modest. A meta-analysis of 8 randomized placebo-controlled trials found juice lowered systolic pressure by 4.96 mmHg (95% CI 2.25 to 7.67) and diastolic by 2.01 mmHg (95% CI 0.31 to 3.71), from small trials in mixed groups of adults. That comes in a glass of sugar. A 248 g glass of 100 percent juice carries about 134 calories and 31 g of sugars in US survey data, with 531 mg of potassium and almost no vitamin C. The inflammation story is unsettled. An updated meta-analysis of 11 trials with 696 people, largely from Iran, found C-reactive protein fell by 2.55 mg/L. An earlier one of 5 trials with 427 people found a change of 0.22 mg/L that did not reach significance, and the newer pooling showed no link to dose or duration.

Every statement here is tied to a source. The badge says what kind of evidence stands behind it: A is a meta-analysis or systematic review, E is the position of an expert body without its own analysis. How we verify →

The numbers, per 3.5 oz (100 g)

USDA entry	kcal	Protein	Fat	Carbs	Fiber
Juice, pomegranate, from concentrate, shelf-stable	—	0 g	— g	— g	— g
Pomegranate juice, bottled	54	0.15 g	0.29 g	13.1 g	0.1 g

These are the USDA entries that are pomegranate juice, not foods made from it; they differ in cut, part, pack or preparation. Linked names have a page with the full profile and per-portion figures.

As people eat it, per 3.5 oz (100 g)

As eaten	kcal	Protein	Fat	Carbs	Fiber
Pomegranate juice, 100%	54	0.15 g	0.29 g	13.1 g	0.1 g

USDA Food and Nutrient Database for Dietary Studies (FNDDS, release 2024-10-31): pomegranate juice as it is prepared and served, from the recipes behind the national dietary survey, rather than a single laboratory sample.

How much is actually in it

A typical 248 g glass of 100% pomegranate juice carries about 134 calories, 31 g sugars and 531 mg potassium, with almost no vitamin C. — US household measures, FNDDS (n = 1 food code) Evidence E source
Per 100 g: 54 calories, total sugars 12.65 g, potassium 214 mg, vitamin C 0.1 mg; per 248 g: 133.9 calories, 31.4 g, 530.7 mg, 0.2 mg; 1 fl oz 31 g

What a real portion looks like

A typical 248 g glass of 100% pomegranate juice carries about 134 calories and 31 g of sugars, plus 531 mg potassium. — US household measures, FNDDS (n = 1 food code) Evidence E source
Per 248 g: 133.9 calories, total sugars 31.4 g, potassium 530.7 mg
A typical 248 g glass of 100% pomegranate juice carries about 134 calories and 31 g of sugars, plus 531 mg potassium. — US household measures, FNDDS (n = 1 food code) Evidence E source
Per 248 g: 133.9 calories, total sugars 31.4 g, potassium 530.7 mg

What your body absorbs

In a randomized crossover, one 8 fl oz (237 mL) glass of pomegranate juice with about 120 mg ellagic acid gave the same plasma ellagic acid as a 500 mg ellagic acid supplement. — healthy volunteers, single dose of 8 fl oz (237 mL) juice (about 120 mg ellagic acid) vs 500 mg free ellagic acid Evidence B source
No difference in plasma ellagic acid despite about 4 times less ellagic acid in juice, higher urinary metabolite after juice
Drunk with white bread, pomegranate juice cut the blood glucose rise by 33% in 16 healthy adults compared with a drink of equal sugar, while a pomegranate extract did not. — 16 healthy volunteers per study, bread with juice or control solution of equivalent sugars, single meals (n = 16) Evidence B source
Bread glucose iAUC -33.1% +/- 18.1% (P=0.000005), peak glucose attenuated 25.4%

What cooking and storage change

A 4.2 fl oz (125 mL) serving of Wonderful pomegranate juice pressed from arils and whole fruit with peels provided 450 mg polyphenols, about 80% ellagitannins. — trial beverage analyzed in the lab, cultivar Wonderful Evidence D source
450 mg (poly)phenols per 125 mL, about 80% ellagitannins; two servings a day gave over 700 mg ellagitannins vs 5-12 mg/day average European intake

What it does to your health

A 2023 meta-analysis of 14 trials with 573 people found pomegranate juice lowered systolic blood pressure by about 5 mm Hg. — participants in clinical trials of pomegranate juice alone, human studies in English (n = 14 trials, 573 individuals) Evidence A source
SBP MD -5.02 mm Hg (95% CI -7.55 to -2.48)
In the 14-trial meta-analysis, up to 10 fl oz (300 mL) of pomegranate juice a day cut systolic pressure by about 6 mm Hg, while more than 10 fl oz (300 mL) a day did not clearly lower it. — participants in clinical trials of pomegranate juice alone (n = 14 trials, 573 individuals) Evidence A source
<=300 mL/day: SBP MD -6.11 mm Hg (95% CI -9.22 to -3.00); >300 mL/day: SBP MD -3.28 mm Hg (95% CI -6.85 to 0.27), DBP MD -3.10 mm Hg (95% CI -5.74 to -0.47)
A 2017 meta-analysis of 8 randomized trials found pomegranate juice lowered systolic pressure both in trials shorter and longer than 12 weeks, by about 4 to 6 mm Hg. — adults in randomized placebo-controlled trials of pomegranate juice (n = 8 RCTs) Evidence A source
>12 weeks: SBP WMD -4.36 mm Hg (95% CI -7.89 to -0.82); <12 weeks: SBP WMD -5.83 mm Hg (95% CI -10.05 to -1.61); <240 mL/day: SBP WMD -11.01 mm Hg (95% CI -17.38 to -4.65)
In a 4-week trial of 51 healthy adults aged 30 to 50, 11 fl oz (330 mL) of pomegranate juice a day lowered systolic pressure by 3.1 mm Hg and diastolic by 2.3 mm Hg. — healthy adults aged 30 to 50 years (n = 51) Evidence B source
SBP -3.14 mm Hg, DBP -2.33 mm Hg, MAP -2.60 mm Hg (all P < 0.001); serum ACE unchanged
An early uncontrolled study in people with high blood pressure found pomegranate juice cut blood ACE activity by 36% and systolic pressure by 5%. — hypertensive patients Evidence C source
Serum ACE activity -36%; SBP -5%
In a crossover RCT of 53 men with mild to moderate erectile dysfunction, 8 fl oz (237 mL) of pomegranate juice daily for 4 weeks did not significantly beat placebo on erection scores. — Men with mild to moderate erectile dysfunction, two 4-week periods with a 2-week washout, Wonderful variety juice vs placebo (n = 53) Evidence B source
25 of 42 improvers improved on juice; P = 0.058 (not significant); testosterone not reported as an outcome
A 2016 meta-analysis of 12 placebo-controlled RCTs with 545 people found no significant effect of pomegranate on total, LDL or HDL cholesterol or triglycerides. — participants of randomized placebo-controlled trials of pomegranate (n = 545 individuals, 12 RCTs) Evidence A source
No significant pooled effect on TC, LDL-C, HDL-C or TG (fixed effects); no link with daily juice amount
The widest meta-analysis, 53 RCTs with 2306 people on any pomegranate product, found no substantial change in LDL or triglycerides against placebo. — adults in RCTs of pomegranate supplementation (juice, extract, seed, peel) (n = 53 RCTs, 2306 participants) Evidence A source
TC SMD -0.12 (95% CI -0.24 to -0.00); HDL SMD 0.27 (0.08 to 0.47); no substantial change in LDL or TG
A 2017 meta-analysis of 8 randomized trials found pomegranate juice lowered systolic blood pressure by about 5 mm Hg and diastolic by about 2 mm Hg. — adults in randomized placebo-controlled trials of pomegranate juice (n = 8 RCTs) Evidence A source
SBP WMD -4.96 mm Hg (95% CI -7.67 to -2.25); DBP WMD -2.01 mm Hg (95% CI -3.71 to -0.31)
A 2024 meta-analysis of 22 trials of pomegranate in any form found systolic blood pressure fell by 7.9 mm Hg and diastolic by 3.2 mm Hg. — adults consuming pomegranate in different forms in randomized clinical trials (n = 22 RCTs) Evidence A source
SBP WMD -7.87 mm Hg (95% CI -10.34 to -5.39); DBP WMD -3.23 mm Hg (95% CI -5.37 to -1.09); heterogeneity I2 90.0% (SBP), 91.8% (DBP)
A 2025 dose-response meta-analysis of 53 trials with 2306 people found pomegranate lowered blood pressure and total cholesterol and raised HDL slightly, with small standardized effects. — participants in randomized controlled trials of pomegranate supplementation published until January 2024 (n = 53 RCTs, 2306 participants) Evidence A source
SBP SMD -0.49 (95% CI -0.68 to -0.31); DBP SMD -0.39 (95% CI -0.59 to -0.18); TC SMD -0.12 (95% CI -0.24 to -0.00); HDL SMD 0.27 (95% CI 0.08 to 0.47)
In a 4-week trial of 51 healthy adults, 11 fl oz (330 mL) of pomegranate juice a day cut systolic pressure by 3.1 mm Hg but did not change arterial stiffness. — healthy adults aged 30 to 50 years (n = 51) Evidence B source
PWV unchanged (P = 0.694); SBP -3.14 mm Hg, DBP -2.33 mm Hg, MAP -2.60 mm Hg (all P < 0.001)
Across 8 randomized placebo-controlled trials, pomegranate juice lowered systolic blood pressure by about 5 mmHg and diastolic by about 2 mmHg. — adults in 8 RCTs, doses under and over 8.1 fl oz (240 mL) a day, durations under and over 12 weeks (n = 8 RCTs) Evidence A source
SBP -4.96 mmHg (95% CI -7.67 to -2.25), DBP -2.01 mmHg (95% CI -3.71 to -0.31)
An updated meta-analysis of 11 trials with 696 people found pomegranate juice lowered C-reactive protein by 2.55 mg/L versus control. — 696 participants in 11 RCTs (13 effect sizes), largely Iranian, type 2 diabetes and PCOS subgroups (n = 696) Evidence A source
CRP -2.55 mg/L (95% CI -3.44 to -1.66)

Safety, limits and interactions

The same review of 8 trials with 619 people found no adverse events with pomegranate juice or capsules. — adults in randomized clinical trials of pomegranate juice or capsules vs control (n = 619 (8 RCTs)) Evidence A source
No adverse events observed
NCCIH says pomegranate usually has no side effects, though some people get digestive symptoms and allergic reactions have been reported. — general public Evidence E source
Digestive symptoms in some; allergic reactions reported
In the 56-day extract trial of 120 men, blood chemistry, liver and kidney markers stayed normal and only five minor adverse events were reported. — Healthy men aged 36-55 on 200 or 400 mg pomegranate rind + cocoa extract or placebo for 56 days (n = 120) Evidence B source
5 minor adverse events (fever, cough and cold, constipation, diarrhea); Cr, AST, ALT, ALP, BUN within normal ranges
A UK emergency case report links pomegranate juice to unstable warfarin anticoagulation and advises asking patients with unstable INR about juice intake. — One middle-aged woman on warfarin with a hematoma and raised INR (n = 1) Evidence D source
Possible increase in warfarin effect; causality not proven
According to NCCIH, pomegranate juice is believed to be safe, though digestive symptoms and allergic reactions have been reported. — general public, US Evidence E source
Juice believed safe; root, stem, peel in large amounts may not be
Three days of 8.5 fl oz (250 mL) pomegranate juice did not significantly change levels of the CYP3A4 probe drug midazolam in 12 adults. — 12 healthy subjects, 8.5 fl oz (250 mL) water, grapefruit or pomegranate juice for 3 days before dapoxetine 60 mg and midazolam 7.5 mg (n = 12) Evidence B source
Pomegranate juice: slight, non-significant changes; grapefruit juice: midazolam AUC +75%
A man taking rosuvastatin and ezetimibe developed severe muscle breakdown three weeks after starting 6.8 fl oz (200 mL) of pomegranate juice twice a week. — one 48-year-old man with possible underlying myopathy on rosuvastatin 5 mg every other day and ezetimibe 10 mg/day (n = 1) Evidence D source
Creatine kinase 138,030 U/L (normal under 200)
A woman on steady warfarin who drank pomegranate juice 2 to 3 times a week had her INR fall below target after she stopped the juice. — one 64-year-old woman on warfarin for recurrent deep vein thrombosis (n = 1) Evidence D source
INR subtherapeutic after stopping juice; warfarin dose raised
Pomegranate can trigger IgE allergy: a 7-year-old with asthma developed bronchospasm moments after eating pomegranate seeds. — one 7-year-old IgE-dependent asthmatic child (n = 1) Evidence D source
Bronchospasm; positive prick-by-prick test; RAST 0.8 PRU/ml
In human volunteers, pomegranate juice did not change clearance of a CYP2C9 probe drug, the enzyme pathway that clears warfarin, although it blocked the enzyme in the test tube. — human volunteers, pomegranate juice or 1 g extract vs low-polyphenol placebo drink, fluconazole as positive control Evidence B source
Flurbiprofen pharmacokinetics unchanged; fluconazole reduced clearance
Three days of 8.5 fl oz (250 mL) pomegranate juice barely changed levels of the CYP3A4 probe midazolam in 12 adults, while grapefruit juice raised them. — 12 healthy subjects, 8.5 fl oz (250 mL) water, grapefruit or pomegranate juice for 3 days before dapoxetine 60 mg and midazolam 7.5 mg (n = 12) Evidence B source
Pomegranate juice: slight, non-significant changes; grapefruit juice: midazolam AUC +75%, dapoxetine AUC +60%
A woman on steady warfarin who drank pomegranate juice 2 to 3 times a week had her INR fall below target after she stopped the juice. — one 64-year-old woman on warfarin 4 mg/day for recurrent deep vein thrombosis (n = 1) Evidence D source
INR became subtherapeutic after stopping juice; warfarin dose raised; possible relationship by Drug Interaction Probability Scale
A man on rosuvastatin and ezetimibe developed severe muscle breakdown three weeks after starting 6.8 fl oz (200 mL) of pomegranate juice twice a week. — one 48-year-old man with possible underlying myopathy on rosuvastatin 5 mg every other day and ezetimibe 10 mg/day (n = 1) Evidence D source
Creatine kinase 138,030 U/L (normal under 200)
In human volunteers, pomegranate juice did not change clearance of flurbiprofen, a CYP2C9 probe drug, although it blocked the enzyme in the test tube. — human volunteers, pomegranate juice or 1 g extract vs low-polyphenol placebo drink, fluconazole as positive control Evidence B source
Flurbiprofen pharmacokinetics unchanged, fluconazole reduced clearance
Three days of 8.5 fl oz (250 mL) pomegranate juice barely changed midazolam or dapoxetine levels in 12 adults, while grapefruit juice raised dapoxetine exposure by 60%. — 12 healthy subjects, 8.5 fl oz (250 mL) water, grapefruit or pomegranate juice for 3 days before 60 mg dapoxetine and 7.5 mg midazolam (n = 12) Evidence B source
Pomegranate juice: slight, non-significant changes; grapefruit: dapoxetine AUC +60%, Cmax +80%, midazolam AUC +75%
Taking 200 mg cyclosporine with 17 fl oz (500 mL) pomegranate juice left its blood levels within the strict bioequivalence range in healthy Thai men. — 14 healthy Thai men aged 20-45 completed, single 200 mg cyclosporine dose with 17 fl oz (500 mL) juice or water, 2 week washout (n = 14) Evidence B source
90% CI of test/control AUC0-t 91.6-105.6, AUC0-inf 92.0-105.2, Cmax 82.3-102.5
A 64-year-old woman on steady warfarin drinking pomegranate juice 2-3 times a week had INR fall below target after stopping the juice. — one 64-year-old woman on warfarin 4 mg/day for recurrent deep vein thrombosis (n = 1) Evidence D source
INR became subtherapeutic after stopping juice, warfarin dose raised; possible relationship by Drug Interaction Probability Scale
A 48-year-old man on rosuvastatin and ezetimibe developed rhabdomyolysis three weeks after starting 6.8 fl oz (200 mL) pomegranate juice twice weekly. — one 48-year-old man with possible underlying myopathy, rosuvastatin 5 mg every other day and ezetimibe 10 mg/day (n = 1) Evidence D source
Creatine kinase 138,030 U/L (normal under 200)

What people believe that the data does not support

The US National Center for Complementary and Integrative Health says pomegranate juice or extract may help lower blood pressure but more research is needed. — general public Evidence E source
Possible benefit, unconfirmed
A 2024 systematic review of 52 studies on 27 testosterone boosters found most fail to raise total testosterone, and rated the pomegranate rind and cocoa blend only possibly effective in late-onset hypogonadism. — Male athletes, men with late-onset hypogonadism, infertile men and healthy men in 52 studies of 27 supplements (n = 52 studies) Evidence A source
Most boosters no increase in total testosterone vs placebo; pomegranate rind + cocoa blend 'possibly effective' for late-onset hypogonadism; no pomegranate juice study listed
The EU did not authorize a claim that a pomegranate pomace extract with galangal increases the number of motile sperm. — EU food labeling Evidence E source
Claim non-authorized
A meta-analysis of 128 RCTs of polyphenol-rich foods found pomegranate lowered total cholesterol less clearly than nuts and berries did. — participants of RCTs of berries, red grapes or wine, nuts and pomegranate (n = 128 RCTs) Evidence A source
Total cholesterol reduced by ellagitannin and anthocyanin products; nuts and berries more significant than pomegranate and grapes
According to NCCIH (2025), studies of pomegranate products have not shown clear effects on cholesterol or other blood lipids. — general public, US Evidence E source
No clear effect on cholesterol and lipids
A 2016 meta-analysis of 12 trials with 545 people found pomegranate did not change blood lipids. — individuals in randomized placebo-controlled trials of pomegranate and plasma lipids (n = 545 (12 RCTs, 13 arms)) Evidence A source
No significant effect on total cholesterol, LDL-C, HDL-C or triglycerides
The EU did not authorize the health claim that pomegranate juice supports the cardiovascular system. — EU food labeling Evidence E source
Claim non-authorized
An earlier meta-analysis of 5 trials with 427 people found no clear change in C-reactive protein with pomegranate juice. — 427 participants in 5 RCT arms, 216 on juice and 211 controls (n = 427) Evidence A source
CRP -0.22 mg/L (95% CI -0.45 to 0.01), not significant
Across 15 RCTs with 673 people, pomegranate products including juice did not change insulin resistance measured by HOMA-IR. — 673 participants in 15 RCTs in 7 countries, at least 4 weeks of juice, seed oil, peel extract or peel-added bread (n = 673) Evidence A source
HOMA-IR WMD -0.03 (95% CI -0.37 to 0.31), fasting insulin WMD -0.03 (95% CI -0.42 to 0.36)
The EU did not authorize the claim that pomegranate juice plays an important antioxidative function and supports the cardiovascular system. — EU food labeling Evidence E source
Claim non-authorized
The EU also did not authorize the claim that pomegranate juice phenolic compounds help maintain cholesterol and lipid levels. — EU food labeling Evidence E source
Claim non-authorized

Who this works differently for

A 2024 meta-analysis of 22 trials of pomegranate in any form found a larger fall in systolic pressure in people starting above 130 mm Hg. — adults consuming pomegranate in different forms in randomized clinical trials, searched to January 2024 (n = 22 RCTs) Evidence A source
Greater SBP reduction with baseline SBP > 130 mm Hg vs < 130 mm Hg; size of the difference not given in abstract
In 21 adults with high blood pressure, 5.1 fl oz (150 mL) of fresh pomegranate juice a day for 2 weeks lowered systolic and diastolic pressure compared with water. — hypertensive patients aged 30 to 67 years (n = 21 (11 juice, 10 water)) Evidence B source
Significant reductions in SBP (p = 0.002) and DBP (p = 0.038); FMD unchanged; mm Hg size not given in abstract
In 60 people with type 2 diabetes, 6.8 fl oz (200 mL) of pomegranate juice a day for 6 weeks left systolic and diastolic pressure lower than in a no-juice group. — patients with type 2 diabetes, Iran (n = 60 (30 per group)) Evidence B source
SBP and DBP lower than control after 6 weeks (P < 0.02 and P < 0.03); size of between-group difference not given
In women with polycystic ovary syndrome, 10 fl oz (300 mL) a day of pomegranate juice for 8 weeks left blood pressure lower than a placebo drink. — women with polycystic ovary syndrome, Iran Evidence B source
BP lower than placebo in pomegranate juice (P < 0.01) and synbiotic pomegranate juice (P < 0.001) groups; size not given in abstract
In 24 people on hemodialysis, 3.4 fl oz (100 mL) of pomegranate juice before each session for 4 weeks did not change pre-dialysis blood pressure and was well tolerated. — patients on maintenance hemodialysis, 64% men, mean age 61 years (n = 24) Evidence B source
No significant effect on predialysis systolic or diastolic BP; safe and well tolerated
A 2025 meta-analysis in women with polycystic ovary syndrome found pomegranate juice for 8 weeks lowered serum testosterone slightly versus control, pooled from 2 trials with 85 women. — Overweight women aged 15 to 48 with PCOS (Rotterdam criteria), 4 Iranian RCTs, 128 women; testosterone pooled from 2 trials (n = 85) Evidence A source
Testosterone MD -0.05 (95% CI -0.07 to -0.03), I2 = 0%, 2 studies, 85 participants; rated high-quality by the authors
In a triple-blind RCT of 92 women with PCOS drinking 2.1 quarts (2 L) a week for 8 weeks, testosterone fell with synbiotic pomegranate juice and with a synbiotic drink without pomegranate, but not with plain pomegranate juice. — Women with polycystic ovary syndrome, 4 arms of 23 (synbiotic pomegranate juice, pomegranate juice, synbiotic beverage, placebo), 2.1 quarts (2 L) weekly (n = 92) Evidence B source
Testosterone decreased significantly in synbiotic pomegranate juice and synbiotic beverage groups; no significant change reported for the plain juice arm
In a double-blind crossover trial in 9 elite weightlifters, plasma testosterone 3 minutes after training was lower after pomegranate juice than after placebo. — Nine elite weightlifters aged about 21, two Olympic weightlifting sessions after pomegranate juice or placebo (n = 9) Evidence B source
Plasma testosterone lower with juice vs placebo 3 min post exercise (p = 0.012); homocysteine -14% over 48 h with juice only
A second RCT of the same pomegranate rind and cocoa extract in 120 men aged 21 to 35 found the 400 mg dose raised total testosterone versus placebo over 56 days. — Healthy men aged 21-35, placebo or 200 or 400 mg LN18178 daily for 56 days, 40 per group (n = 120) Evidence B source
Free testosterone up with both doses (p = 0.0268 and p < 0.0001 vs placebo); total testosterone up with 400 mg only (p = 0.0184 vs placebo)
A 2026 meta-analysis of 17 RCTs with 663 adults found pomegranate juice lowered LDL by 4.8 mg/dL and triglycerides by 8.2 mg/dL and raised HDL by 2.8 mg/dL. — adults in randomized controlled trials of pomegranate juice reporting lipid outcomes (n = 17 RCTs, 663 participants) Evidence A source
TG MD -8.2 mg/dL; LDL-C MD -4.8 mg/dL; HDL-C MD +2.8 mg/dL; TC no overall effect; high heterogeneity; effects larger in metabolic disorders
In type 2 diabetes, a 2020 meta-analysis of 7 RCTs with 350 people found pomegranate did not significantly change blood lipids or other metabolic markers. — adults with type 2 diabetes in RCTs of pomegranate supplementation (n = 7 trials, 350 participants) Evidence A source
No significant effect on TG, TC, HDL-C, LDL-C, glycemic or oxidative stress markers
In 60 people with type 2 diabetes, 6.8 fl oz (200 mL) of pomegranate juice a day for 6 weeks did not change cholesterol or triglycerides compared with no juice. — patients with type 2 diabetes, Iran, 200 mL/day for 6 weeks vs no intervention (n = 60 (30 per group)) Evidence B source
TC, TG, LDL-C and HDL-C no between-group difference; TC and LDL-C fell only within the juice group
In an 8-week triple-blind trial in women with PCOS, 10 fl oz (300 mL) a day of pomegranate juice raised HDL compared with placebo, while lower total cholesterol and LDL were seen only in the synbiotic drink groups. — females with polycystic ovary syndrome, 300 mL/day pomegranate juice, synbiotic beverage, synbiotic pomegranate juice or placebo Evidence B source
Vs placebo: HDL-c higher with PJ and synbiotic PJ (P < 0.01); TC lower only with synbiotic beverage; LDL-c lower with synbiotic drinks
In a non-randomized before-after study of 22 people with diabetes and high cholesterol, 40 g a day of concentrated juice for 8 weeks was followed by lower total and LDL cholesterol. — type II diabetic patients with hyperlipidemia (cholesterol >= 201 mg/dL (5.2 mmol/L) or TG >= 204 mg/dL (2.3 mmol/L)), Iran (n = 22) Evidence C source
TC (P < .006) and LDL-C (P < .006) fell; TG and HDL unchanged
In 24 people on hemodialysis, 3.4 fl oz (100 mL) of pomegranate juice before each session for 4 weeks was safe but did not change lipids or blood pressure. — patients on maintenance hemodialysis, mean age 61 years (n = 24) Evidence B source
Safe and well tolerated; no change in lipids, inflammation, oxidative stress or predialysis BP
In 60 people with type 2 diabetes, 6.8 fl oz (200 mL) of pomegranate juice a day for 6 weeks lowered blood pressure versus no juice but did not change blood lipids. — patients with type 2 diabetes, Iran (n = 60 (30 per group)) Evidence B source
SBP and DBP lower than control after 6 weeks (P < 0.02, P < 0.03); TC, TG, LDL-C, HDL-C no between-group difference
In 24 people on maintenance hemodialysis, 3.4 fl oz (100 mL) of pomegranate juice before each session for 4 weeks was safe but did not change blood pressure, lipids or inflammation. — patients on maintenance hemodialysis, 64% men, mean age 61 years (n = 24) Evidence B source
Safe and well tolerated; no change in lipids, CRP, IL-6, F2-isoprostanes or predialysis SBP/DBP
In 24 hemodialysis patients, 3.4 fl oz (100 mL) pomegranate juice before each session for 4 weeks was safe but did not change inflammation, oxidative stress or blood pressure. — 24 maintenance hemodialysis patients (64% men, mean age 61), 3.4 fl oz (100 mL) juice before each session or 1,050 mg extract daily, 4-week crossover periods (n = 24) Evidence B source
Safe and well tolerated, no significant change in lipids, CRP, IL-6, F2-isoprostanes or predialysis blood pressure
In 99 pregnancies with fetal growth restriction, 8 oz of pomegranate juice daily until delivery was linked to lower infant brain injury risk than placebo juice. — 99 mothers with IUGR diagnosed at 24-34 weeks, 8 oz pomegranate (n=56) or placebo (n=47) juice daily to delivery, 57 infants scanned (n = 99) Evidence B source
No difference in brain volumes or white matter, lower risk of any white or cortical gray matter injury with pomegranate; no ductal constriction on fetal echo

What is still unknown

In the same 14-trial meta-analysis the fall in blood pressure showed up in trials of 2 months or less and was lost in longer ones. — participants in clinical trials of pomegranate juice alone (n = 14 trials, 573 individuals) Evidence A source
Duration <=2 months: SBP MD -4.59 mm Hg (95% CI -7.10 to -2.08), DBP MD -2.94 mm Hg (95% CI -5.25 to -0.63); benefit lost after 2 months
A 2017 systematic review of 8 trials with 619 people found only 2 trials showed a clear fall in systolic pressure, while 3 found no difference and 3 did not report one. — adults in randomized clinical trials of pomegranate juice or capsules vs control (n = 619 (8 RCTs)) Evidence A source
SBP: 2 of 8 trials significant reduction, 3 no between-group difference, 3 between-group results not reported
In an RCT of 120 men aged 36 to 55, a capsule of pomegranate rind and cocoa seed extract for 56 days raised total testosterone by about 21 to 25% from baseline. This was an extract, not juice. — Healthy men aged 36-55, placebo or 200 or 400 mg LN18178 (Punica granatum fruit rind + Theobroma cocoa seed extract) daily for 56 days, 40 per group (n = 120) Evidence B source
Free testosterone +39.16% and +48.28%, total testosterone +21.39% and +24.56% from baseline (200 and 400 mg); increases also significant vs placebo
In the longest trial, 289 adults at moderate heart risk drank 8.1 fl oz (240 mL) of pomegranate juice or a control drink for up to 18 months, with no overall difference in carotid artery thickening. — men 45-74 and women 55-74 years with at least 1 major CHD risk factor (n = 289 (146 juice, 143 control)) Evidence B source
No difference in overall CIMT progression; slower progression only in exploratory subgroups with adverse TG/HDL profile
The same 53-trial meta-analysis found no change in LDL cholesterol or triglycerides with pomegranate. — participants in randomized controlled trials of pomegranate supplementation (n = 53 RCTs, 2306 participants) Evidence A source
No substantial change in LDL, triglycerides, HbA1c, insulin, HOMA-IR, waist measures or liver enzymes vs placebo
A 2017 systematic review of 8 trials with 619 people judged the evidence that pomegranate lowers blood pressure weak, with trials of mixed quality. — adults in randomized clinical trials of pomegranate juice or capsules vs control (n = 619 (8 RCTs)) Evidence A source
2 of 8 trials showed significant SBP fall, 3 no difference, 3 did not report between-group results; no adverse events
In an 18-month trial of 289 adults at moderate heart disease risk, 8.1 fl oz (240 mL) of pomegranate juice a day did not slow thickening of the carotid artery wall. — men 45 to 74 and women 55 to 74 years with at least one major coronary risk factor and posterior wall CIMT 0.7 to 2.0 mm (n = 289 (146 juice, 143 control)) Evidence B source
No significant difference in overall CIMT progression rate

The bottom line

Insulin resistance did not move. Across 15 trials with 673 people, pomegranate products did not change HOMA-IR, and that pooling mixed juice with seed oil, peel extract and peel-added bread. Drunk with white bread in 16 healthy adults, juice cut the blood glucose rise from the bread by 33 percent against a drink with the same sugar, in single meals. The sugar in the juice itself still counts. The EU refused claims that the juice supports the cardiovascular system or helps maintain cholesterol, which means the evidence did not meet the bar when it was assessed. Worries about drug interactions mostly did not hold up in controlled studies. In human volunteers, juice did not change clearance of flurbiprofen, a probe for the CYP2C9 enzyme, although it blocked that enzyme in the test tube. In 12 healthy adults, three days of 8.5 fl oz (250 mL) did not significantly change midazolam or dapoxetine levels, while grapefruit juice raised dapoxetine exposure by 60 percent. With a single 200 mg dose of cyclosporine, 17 fl oz (500 mL) of juice left blood levels within the bioequivalence range in 14 healthy men, and repeated daily juice was not tested. Two single case reports stand against that. A woman on warfarin saw her INR fall below target after she stopped drinking the juice, with no rechallenge. A man with possible underlying muscle disease on rosuvastatin and ezetimibe developed rhabdomyolysis three weeks after starting 6.8 fl oz (200 mL) twice a week, and causality is uncertain. If you take warfarin or a statin, mention the juice to whoever manages the drug. In a 4-week pilot in 24 people on hemodialysis, 3.4 fl oz (100 mL) before each session was well tolerated and did not change inflammation, oxidative stress or blood pressure. The potassium in a glass matters for anyone on dialysis. In an exploratory trial of 99 pregnancies with fetal growth restriction, 8 oz a day until delivery was linked with lower risk of infant brain injury on scans of 57 babies, with no size given in the abstract and no difference in brain volumes. Fetal heart scans showed no ductal constriction. This is one exploratory trial in a condition under medical care, and it does not establish the juice as a treatment for growth restriction.

Questions about pomegranate juice, answered from the trials

Related foods

Pomegranate: the juice, the capsule and eleven refusals

Guides that discuss this food

Polyphenols: what tea, fruit and supplements actually do

Sources

pomj-r3-01 · reference dataset
FNDDS 2709330 Pomegranate juice, 100% (64126000): Energy 54 kcal/100 g, Quantity not specified 248 g 133.9 kcal · Total Sugars 12.65 g/100 g, 248 g 31.4 g · Potassium, K 214 mg/100 g, 248 g 530.7 mg · Vitamin C, total ascorbic acid 0.1 mg/100 g, 248 g 0.2 mg · 1 fl oz (no ice) 31 g
USDA FNDDS 2021-2023 · checked 2026-09-29
ev-pomjch-16 · reference dataset
FNDDS 2709330 Pomegranate juice, 100% (64126000): Energy 54 kcal/100 g, Quantity not specified 248 g 133.9 kcal · Total Sugars 12.65 g/100 g, 248 g 31.4 g · Potassium, K 214 mg/100 g, 248 g 530.7 mg · Vitamin C, total ascorbic acid 0.1 mg/100 g, 248 g 0.2 mg · 1 fl oz (no ice) 31 g
USDA FNDDS 2021-2023 · checked 2026-10-07
ev-pomjhh-16 · reference dataset
FNDDS 2709330 Pomegranate juice, 100% (64126000): Energy 54 kcal/100 g, Quantity not specified 248 g 133.9 kcal · Total Sugars 12.65 g/100 g, 248 g 31.4 g · Potassium, K 214 mg/100 g, 248 g 530.7 mg · Vitamin C, total ascorbic acid 0.1 mg/100 g, 248 g 0.2 mg · 1 fl oz (no ice) 31 g
USDA FNDDS 2021-2023 · checked 2026-10-07
pomj-r3-03 · randomized crossover trial
To conclude, one serving of PomJ provided the same level of EA in blood, while the increase in phase II metabolism of EA and an acute suppression of plasma MCP1 were only observed after PomJ consumption
Food Funct, 2019 · checked 2026-09-29
pomj-r3-04 · randomized crossover trial
the incremental area under the curve for bread-derived blood glucose (-33.1% ± 18.1%, P = 0.000005) and peak blood glucose (25.4% ± 19.3%, P = 0.0004) were attenuated by pomegranate juice, compared with a control solution containing the equivalent amount of sugars.
Am J Clin Nutr, 2017 · checked 2026-09-29
pomj-r3-02 · in vitro beverage analysis
One serving (125 mL) of POMJ made from arils and whole fruit with peels provided 450 mg of (poly)phenols, of which approximately 80% was ETs.
Mol Nutr Food Res, 2025 · checked 2026-09-29
ev-pjbp-01 · meta-analysis of clinical trials
Meta-analysis of 14 clinical trials (n = 573 individuals) demonstrated a reduction in systolic BP (SBP) with pomegranate juice (MD: -5.02 mmHg, 95% CI: -7.55 to -2.48, p < 0.001).
Phytotherapy Research, 2023 (impact of pomegranate juice on blood pressure: systematic review and meta-analysis) · checked 2026-10-07
ev-pjbp-03 · meta-analysis of clinical trials
Consumption of ≤300 mL pomegranate juice daily reduced SBP (MD: -6.11 mmHg, 95% CI: -9.22 to -3.00, p < 0.001).
Phytotherapy Research, 2023 (impact of pomegranate juice on blood pressure: systematic review and meta-analysis) · checked 2026-10-07
ev-pjbp-04 · meta-analysis of randomized controlled trials
Pomegranate juice reduced SBP regardless of the duration (>12 wks: WMD=-4.36mmHg, 95% CI: -7.89 to -0.82, p=0.016) and <12 wks: WMD=-5.83 mmHg, 95% CI: -10.05 to -1.61, p=0.007) and dose consumed (>240cc: WMD=-3.62mmHg, 95% CI: -6.62 to -0.63, p=0.018) and <240cc: WMD=-11.01mmHg, 95% CI: -17.38 to -4.65, p=0.001, pomegranate juice per day) whereas doses >240cc provided a borderline significant effect in reducing DBP.
Pharmacol Res, 2017 · checked 2026-10-07
ev-pjbp-08 · randomized controlled trial
However, there was a significant fall in systolic blood pressure (-3.14 mmHg, P < 0.001), diastolic blood pressure (-2.33 mmHg P < 0.001) and mean arterial pressure (-2.60 mmHg, P < 0.001).
Plant Foods Hum Nutr, 2012 · checked 2026-10-07
ev-pjbp-13 · non-randomized intervention study
A 36% decrement in serum ACE activity and a 5% reduction in systolic blood pressure were noted.
Atherosclerosis, 2001 (pomegranate juice, serum ACE activity and systolic blood pressure) · checked 2026-10-07
ev-pjt-04 · RCT
Subjects were more likely to have improved scores when pomegranate juice was consumed (P=0.058).
Forest et al., International Journal of Impotence Research, 2007 · checked 2026-10-07
ev-pomjch-02 · meta-analysis of randomized controlled trials
Fixed-effect meta-analysis of data from 12 RCTs (13 treatment arms) did not show any significant effect of pomegranate consumption on plasma lipid concentrations.
Phytomedicine, 2016 · checked 2026-10-07
ev-pomjch-03 · meta-analysis of randomized controlled trials
No substantial changes were observed in waist-to-hip ratio (WHR), homeostatic model assessment of insulin resistance (HOMA-IR), waist circumference (WC), serum values of hemoglobin A1c (HbA1c), alanine transaminase (ALT), triglycerides (TG), low-density lipoprotein (LDL), insulin, and aspartate transferase (AST) levels between PO and placebo groups.
Nutr Metab Cardiovasc Dis, 2025 · checked 2026-10-07
ev-pomjhh-01 · meta-analysis of randomized controlled trials
Quantitative data synthesis from 8 RCTs showed significant reductions in both systolic [weighed mean difference (WMD): -4.96mmHg, 95% CI: -7.67 to -2.25, p<0.001) and diastolic BP (WMD: -2.01mmHg, 95% CI: -3.71 to -0.31, p=0.021) after pomegranate juice consumption.
Pharmacol Res, 2017 · checked 2026-10-07
ev-pomjhh-02 · meta-analysis of randomized controlled trials
Our meta-analysis of the pooled findings showed that pomegranate consumption significantly reduced SBP (WMD: -7.87 mmHg; 95% CI: -10.34 to -5.39; p < 0.001) and DBP (WMD: -3.23 mmHg; 95% CI: -5.37 to -1.09; p = 0.003).
Phytotherapy Research, 2024 (pomegranate consumption and blood pressure in adults: systematic review and meta-analysis) · checked 2026-10-07
ev-pomjhh-03 · meta-analysis of randomized controlled trials
The findings revealed that PO supplementation substantially reduced body weight (standardized mean difference (SMD): -0.14 kg, 95 % CI: -0.25, -0.03; P = 0.01), diastolic blood pressure (DBP) (SMD: -0.39 mmHg, 95 % CI: -0.59, -0.18; P < 0.001), body mass index (BMI) (SMD: -0.17 kg/m2, 95 % CI: -0.30, -0.04; P = 0.01), systolic blood pressure (SBP) (SMD: -0.49 mmHg, 95 % CI: -0.68, -0.31; P < 0.001), serum fasting blood glucose (FBG) (SMD: -0.15 mg/dL, 95 % CI: -0.26, -0.04; P = 0.01), and total cholesterol (TC) (SMD: -0.12 mg/dL, 95 % CI: -0.24, -0.00; P = 0.04) while elevating high-density lipoprotein (HDL) levels (SMD: 0.27 mg/dL, 95 % CI: 0.08, 0.47; P < 0.001) compared to control groups.
Nutr Metab Cardiovasc Dis, 2025 · checked 2026-10-07
ev-pomjhh-08 · randomized controlled trial
We conclude that pomegranate juice supplementation has benefits for BP in the short term, but has no effect on PWV.
Plant Foods Hum Nutr, 2012 · checked 2026-10-07
pomj-r3-05 · meta-analysis of RCTs
Quantitative data synthesis from 8 RCTs showed significant reductions in both systolic [weighed mean difference (WMD): -4.96mmHg, 95% CI: -7.67 to -2.25, p<0.001) and diastolic BP (WMD: -2.01mmHg, 95% CI: -3.71 to -0.31, p=0.021) after pomegranate juice consumption.
Pharmacol Res, 2017 · checked 2026-09-29
pomj-r3-06 · meta-analysis of RCTs
Meta-analysis showed that PJ supplementation led to a significant decrease in CRP levels compared to control groups (WMD: -2.55 mg/L; 95%CI: -3.44 to -1.66; p < 0.001).
Phytother Res, 2024 · checked 2026-09-29
ev-pjbp-07 · systematic review of randomized controlled trials
No adverse events were observed.
Nutr Res, 2017 · checked 2026-10-07
ev-pjbp-15 · agency position
Pomegranate usually doesn’t have side effects, but some people may have digestive tract symptoms. Allergic reactions to pomegranate have been reported.
NIH NCCIH, Pomegranate (fact sheet, last updated April 2025) · checked 2026-10-07
ev-pjt-06 · RCT
Overall, the participants reported only five minor adverse events: fever, cough & cold, constipation, and diarrhea during the study (Table 7).
International Journal of Medical Sciences, 2022, 19(8):1290-1299 · checked 2026-10-07
ev-pjt-10 · case report
As with previous reports of interactions between food and warfarin, this case does not definitively prove the association between pomegranate juice consumption and increased warfarin bioactivity but highlights the importance of taking a complete drug, food and juice history when assessing patients with unstable anticoagulation.
Emerg Med J, 2010 · checked 2026-10-07
ev-pomjch-11 · agency position
Pomegranate juice is believed to be safe.
NIH National Center for Complementary and Integrative Health, Pomegranate: Usefulness and Safety, updated April 2025 · checked 2026-10-07
ev-pomjch-12 · randomized pharmacokinetic trial
Slight but not statistically significant changes were observed in the pharmacokinetics of dapoxetine and midazolam after pretreatment with PJ.
Eur J Drug Metab Pharmacokinet, 2017 · checked 2026-10-07
ev-pomjch-13 · case report
Three weeks before presentation, he began drinking pomegranate juice (200 ml twice weekly). He presented urgently with thigh pain and an elevated serum creatine kinase level (138,030 U/L, normal < 200 U/L).
Am J Cardiol, 2006 · checked 2026-10-07
ev-pomjch-14 · case report
During that time, the patient was consuming pomegranate juice 2-3 times/week. She stopped drinking the juice, and her INRs became subtherapeutic.
Pharmacotherapy, 2009 · checked 2026-10-07
ev-pomjch-17 · case report
We present the case of a 7-year-old IgE-dependent asthmatic child who, moments after ingesting several pomegranate seeds, showed a clinical condition of bronchospasm which responded to treatment with inhaled salbutamol.
J Investig Allergol Clin Immunol, 1992 · checked 2026-10-07
ev-pomjhh-11 · randomized pharmacokinetic trial
Despite inhibition of CYP2C9 in vitro, pomegranate juice and extract had no effect on CYP2C9 activity in human subjects, and can be consumed by patients taking CYP2C9 substrate drugs with negligible risk of a pharmacokinetic interaction.
Clin Pharmacol Ther, 2012 · checked 2026-10-07
ev-pomjhh-12 · randomized pharmacokinetic trial
Slight but not statistically significant changes were observed in the pharmacokinetics of dapoxetine and midazolam after pretreatment with PJ.
Eur J Drug Metab Pharmacokinet, 2017 · checked 2026-10-07
ev-pomjhh-13 · case report
During that time, the patient was consuming pomegranate juice 2-3 times/week. She stopped drinking the juice, and her INRs became subtherapeutic.
Pharmacotherapy, 2009 · checked 2026-10-07
ev-pomjhh-14 · case report
Three weeks before presentation, he began drinking pomegranate juice (200 ml twice weekly). He presented urgently with thigh pain and an elevated serum creatine kinase level (138,030 U/L, normal < 200 U/L).
Am J Cardiol, 2006 · checked 2026-10-07
pomj-r3-09 · randomized pharmacokinetic trial
Despite inhibition of CYP2C9 in vitro, pomegranate juice and extract had no effect on CYP2C9 activity in human subjects, and can be consumed by patients taking CYP2C9 substrate drugs with negligible risk of a pharmacokinetic interaction.
Clin Pharmacol Ther, 2012 · checked 2026-09-29
pomj-r3-10 · randomized pharmacokinetic trial
Slight but not statistically significant changes were observed in the pharmacokinetics of dapoxetine and midazolam after pretreatment with PJ.
Eur J Drug Metab Pharmacokinet, 2017 · checked 2026-09-29
pomj-r3-11 · randomized pharmacokinetic trial
Single dose administration of pomegranate juice with cyclosporine did not significantly affect the oral bioavailability of cyclosporine.
Curr Clin Pharmacol, 2020 · checked 2026-09-29
pomj-r3-12 · case report
During that time, the patient was consuming pomegranate juice 2-3 times/week. She stopped drinking the juice, and her INRs became subtherapeutic.
Pharmacotherapy, 2009 · checked 2026-09-29
pomj-r3-13 · case report
Three weeks before presentation, he began drinking pomegranate juice (200 ml twice weekly). He presented urgently with thigh pain and an elevated serum creatine kinase level (138,030 U/L, normal < 200 U/L).
Am J Cardiol, 2006 · checked 2026-09-29
ev-pjbp-14 · agency position
Pomegranate juice or extract may be helpful in reducing blood pressure, but additional research is needed to confirm this effect.
NIH NCCIH, Pomegranate (fact sheet, last updated April 2025) · checked 2026-10-07
ev-pjt-08 · systematic review
Eurycoma longifolia, a blend of Punica granatum fruit rind and Theobroma cacao seed extracts (Tesnor™) and purified Shilajit extract (PrimaVie™) can be considered possibly effective for men with late-onset hypogonadism; Eurycoma longifolia and Withania somnifera possibly effective for healthy men; and a non-hormonal aromatase inhibitor (Novadex XT™) possibly effective for male athletes.
Int J Impot Res, 2024 · checked 2026-10-07
ev-pjt-09 · EU claim register entry
POL-HC-8484 A combination of pomegranate pomace extract and greater galangal rhizome powder A combination of standardised pomegranate pomace extract and greater galangal rhizome powder increases the number of motile spermatozoa in semen. -/- Non-authorised
EU Register on nutrition and health claims, claim POL-HC-8484, snapshot 2026-09-21 · checked 2026-10-07
ev-pomjch-05 · meta-analysis of randomized controlled trials
Both anthocyanin- and ellagitannin-containing products reduced total-cholesterol with nuts and berries yielding more significant effects than pomegranate and grapes.
Int J Mol Sci, 2018 · checked 2026-10-07
ev-pomjch-10 · agency position
Studies have been done to see whether various products from pomegranate can influence levels of cholesterol and other lipids, but no clear effects have been demonstrated.
NIH National Center for Complementary and Integrative Health, Pomegranate: Usefulness and Safety, updated April 2025 · checked 2026-10-07
ev-pomjhh-05 · meta-analysis of randomized controlled trials
Fixed-effect meta-analysis of data from 12 RCTs (13 treatment arms) did not show any significant effect of pomegranate consumption on plasma lipid concentrations.
Phytomedicine, 2016 · checked 2026-10-07
ev-pomjhh-15 · EU claim register entry
POL-HC-7795 Pomegranate juice Pomegranate juice: plays an important antioxidative function; supports the cardiovascular system. Non-authorised
EU Register on nutrition and health claims, claim POL-HC-7795, snapshot 2026-09-21 · checked 2026-10-07
pomj-r3-07 · meta-analysis of RCTs
Meta-analysis of data from 5 eligible randomized controlled trials (RCTs) arms did not provide compelling evidence as to a significant CRP-lowering effect of supplementation with pomegranate juice (WMD: -0.22 mg/l, 95% CI: -0.45, 0.01, p = 0.061).
Phytomedicine, 2016 · checked 2026-09-29
pomj-r3-08 · meta-analysis of RCTs
The summary results showed that compared to the control groups, pomegranate extract had no significant impact on improving HOMA-IR levels in participants (WMD = -0.03, 95%CI: -0.37 to 0.31, and p = 0.851)
Phytother Res, 2025 · checked 2026-09-29
pomj-r3-16 · EU claim register entry
POL-HC-7795 Pomegranate juice Pomegranate juice: plays an important antioxidative function; supports the cardiovascular system. Non-authorised
EU Register on nutrition and health claims, claim POL-HC-7795, snapshot 2026-09-21 · checked 2026-09-29
pomj-r3-17 · EU claim register entry
POL-HC-7793 Pomegranate Juice - phenolic compounds (anthocyanins, tannines, ellagic acid) Helps maintain the cholesterol and lipids levels. Non-authorised
EU Register on nutrition and health claims, claim POL-HC-7793, snapshot 2026-09-21 · checked 2026-09-29
ev-pjbp-05 · meta-analysis of randomized controlled trials
Individuals with baseline SBP > 130 mmHg had a significantly greater reduction in SBP compared to individuals with baseline SBP < 130 mmHg.
Phytotherapy Research, 2024 (pomegranate consumption and blood pressure in adults: systematic review and meta-analysis) · checked 2026-10-07
ev-pjbp-09 · randomized controlled trial
PJ consumption was associated with significant reductions in SBP (p = 0.002) and DBP (p = 0.038) but not FMD (p > 0.05).
Phytotherapy Research, 2014 (blood pressure and endothelial effects of pomegranate juice in hypertensive subjects) · checked 2026-10-07
ev-pjbp-10 · randomized controlled trial
Similarly, SBP and DBP in the intervention group were significantly lower than the control group after intervention (P < 0.02 and P < 0.03, respectively).
Clin Nutr ESPEN, 2019 · checked 2026-10-07
ev-pjbp-11 · randomized controlled trial
Blood pressure (BP) was lower in the SPJ and PJ groups compared to placebo (P < 0.001; P < 0.01, respectively).
J Endocrinol Invest, 2020 · checked 2026-10-07
ev-pjbp-12 · randomized crossover trial
Both pomegranate juice and extract were safe and well tolerated by study participants.
J Ren Nutr, 2015 · checked 2026-10-07
ev-pjt-01 · meta-analysis of RCTs
Decreased significantly (MD: −0.05; 95% CI: −0.07 to −0.03; p < 0.0001; I2 = 0%, two studies, 85 participants).
Journal of Clinical Medicine, 2025, 14(15):5458 · checked 2026-10-07
ev-pjt-02 · RCT
Testosterone level also decreased significantly in the SPJ and SB groups.
Nutr Metab Cardiovasc Dis, 2019 · checked 2026-10-07
ev-pjt-03 · RCT
Compared to PLA, a lower level of plasma testosterone [T] was registered 3 min post exercise using POMj supplementation (p = 0.012) and a significant decrease (p = 0.04, %change = - 14%) in plasma [Hcy] was registered during the 48 h recovery period only using POMj.
J Int Soc Sports Nutr, 2020 · checked 2026-10-07
ev-pjt-07 · RCT
Together, these observations suggest that LN18178 is a safe and tolerable herbal blend; it increases testosterone level and increases muscle strength and MUAC in young, healthy males.
Journal of Dietary Supplements, 2023 (LN18178 trial in young men) · checked 2026-10-07
ev-pomjch-01 · meta-analysis of randomized controlled trials
PJ consumption was associated with significant reductions in TG (MD: -8.2 mg/dL) and LDL-C (MD: -4.8 mg/dL), and a significant increase in HDL-C (MD: +2.8 mg/dL).
Avicenna Journal of Phytomedicine, 2026 (pomegranate juice consumption and lipid profile: updated systematic review and meta-analysis) · checked 2026-10-07
ev-pomjch-04 · meta-analysis of randomized controlled trials
The results of the meta-analysis revealed that pomegranate supplementation did not have any significant effects on metabolic status and oxidative stress biomarkers of subjects with T2DM.
Complement Ther Med, 2020 · checked 2026-10-07
ev-pomjch-06 · randomized controlled trial
At the end of the intervention, TC, TG, LDL-C and HDL-C did not significantly differ between the intervention group and the control group however, TC and LDL-C decreased significantly compared to pre-trial values within the intervention group.
Clin Nutr ESPEN, 2019 · checked 2026-10-07
ev-pomjch-07 · randomized controlled trial
Compared to placebo, Total Cholesterol (TC) was lower in the SB group (P < 0.01), LDL-c was lower in the SPJ and SB groups (P < 0.01), and HDL-c was higher in the SPJ and PJ groups (P < 0.01).
J Endocrinol Invest, 2020 · checked 2026-10-07
ev-pomjch-09 · non-randomized trial
After consumption of CPJ, significant reductions were seen in total cholesterol (P <.006), low-density lipoprotein (LDL)-cholesterol (P <.006), LDL-cholesterol/high-density lipoprotein (HDL)-cholesterol (P <.001), and total cholesterol/HDL-cholesterol (P <.001).
J Med Food, 2004 · checked 2026-10-07
ev-pomjch-15 · randomized crossover trial
Both pomegranate juice and extract are safe and well tolerated by patients undergoing MHD but do not influence markers of inflammation or oxidative stress nor affect predialysis blood pressure.
J Ren Nutr, 2015 · checked 2026-10-07
ev-pomjhh-09 · randomized controlled trial
It is concluded that PJ consumption could decrease systolic and diastolic blood pressure in patients with diabetes while having no effect on lipid profile.
Clin Nutr ESPEN, 2019 · checked 2026-10-07
ev-pomjhh-10 · randomized crossover trial
Both pomegranate juice and extract are safe and well tolerated by patients undergoing MHD but do not influence markers of inflammation or oxidative stress nor affect predialysis blood pressure.
J Ren Nutr, 2015 · checked 2026-10-07
pomj-r3-14 · randomized crossover trial
Both pomegranate juice and extract are safe and well tolerated by patients undergoing MHD but do not influence markers of inflammation or oxidative stress nor affect predialysis blood pressure.
J Ren Nutr, 2015 · checked 2026-09-29
pomj-r3-15 · randomized controlled trial
No significant group differences were found in brain volumes or white matter microstructure; however, infants whose mothers consumed pomegranate juice demonstrated lower risk for brain injury, including any white or cortical grey matter injury compared to placebo.
Sci Rep, 2021 · checked 2026-09-29
ev-pjbp-02 · meta-analysis of clinical trials
Pomegranate juice appeared to decrease SBP and DBP in a dose-dependent manner, but the benefit was lost after 2 months of pomegranate juice intake.
Phytotherapy Research, 2023 (impact of pomegranate juice on blood pressure: systematic review and meta-analysis) · checked 2026-10-07
ev-pjbp-06 · systematic review of randomized controlled trials
Two studies reported significant reductions in systolic blood pressure favoring pomegranate: p = .002 and p < .001 respectively; 3 studies reported no significant differences between groups; and 3 studies failed to report between-group differences.
Nutr Res, 2017 · checked 2026-10-07
ev-pjt-05 · RCT
LN18178 supplementation significantly increased the FT level by 39.16% and 48.28%; the TT level by 21.39% and 24.56% in 200- and 400 mg groups, respectively, from baseline.
International Journal of Medical Sciences, 2022, 19(8):1290-1299 · checked 2026-10-07
ev-pomjch-08 · randomized controlled trial
No significant difference in overall CIMT progression rate was observed between pomegranate juice and control treatments.
Am J Cardiol, 2009 · checked 2026-10-07
ev-pomjhh-04 · meta-analysis of randomized controlled trials
No substantial changes were observed in waist-to-hip ratio (WHR), homeostatic model assessment of insulin resistance (HOMA-IR), waist circumference (WC), serum values of hemoglobin A1c (HbA1c), alanine transaminase (ALT), triglycerides (TG), low-density lipoprotein (LDL), insulin, and aspartate transferase (AST) levels between PO and placebo groups.
Nutr Metab Cardiovasc Dis, 2025 · checked 2026-10-07
ev-pomjhh-06 · systematic review of randomized controlled trials
The limited evidence from clinical trials to date fails to convincingly show a beneficial effect of pomegranate on blood pressure.
Nutr Res, 2017 · checked 2026-10-07
ev-pomjhh-07 · randomized controlled trial
No significant difference in overall CIMT progression rate was observed between pomegranate juice and control treatments.
Am J Cardiol, 2009 · checked 2026-10-07

Review. Reviewed on 2026-09-29 for evidence level, dose and population context, and claims a reader could misread. Bioma Learn has no human medical reviewer at this time, and we say so rather than invent one. Methodology. This is information, not medical advice.